ENTRY       D00964                      Drug
NAME        Letrozole (JAN/USP/INN);
            Femara (TN)
PRODUCT     FEMARA (Novartis Pharmaceuticals Corporation)
  GENERIC   LETROZOLE (A-S Medication Solutions)
            LETROZOLE (Accord Healthcare)
            LETROZOLE (Aurobindo Pharma Limited)
            LETROZOLE (AvKARE)
            LETROZOLE (AvPAK)
            LETROZOLE (Avet Pharmaceuticals)
            LETROZOLE (Breckenridge Pharmaceutical)
            LETROZOLE (Bryant Ranch Prepack)
            LETROZOLE (Bryant Ranch Prepack)
            LETROZOLE (Chartwell RX)
            LETROZOLE (Dr. Reddy's Laboratories Limited)
            LETROZOLE (Natco Pharma Limited)
            LETROZOLE (Proficient Rx LP)
            LETROZOLE (Teva Pharmaceuticals USA)
            LETROZOLE (Yiling Pharmaceutical)
FORMULA     C17H11N5
EXACT_MASS  285.1014
MOL_WEIGHT  285.3027
CLASS       Antineoplastic
             DG01596  Aromatase inhibitor
             DG01524  Triazole antineoplastic
            Metabolizing enzyme substrate
             DG01638  CYP2A6 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
            Metabolizing enzyme inhibitor
             DG01525  CYP2A6 inhibitor
REMARK      Same as: C08163
            Therapeutic category: 2529 4291
            ATC code: L02BG04
            Product: D00964<JP/US>
            Product (mixture): D11068<US>
EFFICACY    Antineoplastic, Estrogen biosynthesis inhibitor
  DISEASE   Breast cancer, postmenopausal (HR-positive) [DS:H00031]
COMMENT     Aromatase inhibitor
TARGET      CYP19A1 (ARO) [HSA:1588] [KO:K07434]
  PATHWAY   hsa00140(1588)  Steroid hormone biosynthesis
METABOLISM  Enzyme: CYP3A4 [HSA:1576], CYP2A6 [HSA:1548]
INTERACTION CYP inhibition: CYP2A6 [HSA:1548]
STR_MAP     map07043  Antineoplastics - hormones
OTHER_MAP   map01522  Endocrine resistance
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L02 ENDOCRINE THERAPY
               L02B HORMONE ANTAGONISTS AND RELATED AGENTS
                L02BG Aromatase inhibitors
                 L02BG04 Letrozole
                  D00964  Letrozole (JAN/USP/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Aromatase Inhibitors
               Letrozole
                D00964  Letrozole (JAN/USP/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              25  Urogenital and anal organ agents
               252  Genital organ agents
                2529  Others
                 D00964  Letrozole (JAN/USP/INN)
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D00964  Letrozole (JAN/USP/INN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01596  Aromatase inhibitor
               D00964  Letrozole
              DG01524  Triazole antineoplastic
               D00964  Letrozole
             Metabolizing enzyme substrate
              DG01638  CYP2A6 substrate
               D00964  Letrozole
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D00964  Letrozole
             Metabolizing enzyme inhibitor
              DG01525  CYP2A6 inhibitor
               D00964  Letrozole
            Drug classes [BR:br08332]
             Antineoplastic
              DG01596  Aromatase inhibitor
               D00964  Letrozole
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Oxidoreductases (EC1)
               Cytochrome P450
                CYP19A1 (ARO)
                 D00964  Letrozole (JAN/USP/INN) &lt;JP/US&gt;
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D00964
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D00964
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D00964
DBLINKS     CAS: 112809-51-5
            PubChem: 7848027
            ChEBI: 6413
            LigandBox: D00964
            NIKKAJI: J390.644B
ATOM        22
            1   C1c C    25.6900  -19.1281
            2   C8y C    26.8966  -19.8333
            3   C8y C    24.4834  -19.8276
            4   N4y N    25.6957  -17.7232
            5   C8x C    26.8907  -21.2381
            6   C8x C    28.1149  -19.1338
            7   C8x C    24.4834  -21.2266
            8   C8x C    23.2710  -19.1222
            9   C8x C    24.5650  -16.9072
            10  N5x N    26.8326  -16.9072
            11  C8x C    28.1033  -21.9376
            12  C8x C    29.3273  -19.8450
            13  C8x C    23.2710  -21.9259
            14  C8x C    22.0527  -19.8276
            15  N5x N    25.0022  -15.5723
            16  C8x C    26.4069  -15.5723
            17  C8y C    29.3216  -21.2498
            18  C8y C    22.0527  -21.2266
            19  C3b C    30.5165  -21.9435
            20  C3b C    20.8402  -21.9202
            21  N3a N    31.7172  -22.6371
            22  N3a N    19.6394  -22.6430
BOND        24
            1     1   2 1
            2     1   3 1
            3     1   4 1
            4     2   5 2
            5     2   6 1
            6     3   7 2
            7     3   8 1
            8     4   9 1
            9     4  10 1
            10    5  11 1
            11    6  12 2
            12    7  13 1
            13    8  14 2
            14    9  15 2
            15   10  16 2
            16   11  17 2
            17   13  18 2
            18   17  19 1
            19   18  20 1
            20   19  21 3
            21   20  22 3
            22   12  17 1
            23   14  18 1
            24   15  16 1
///
